Who Should Be Responsible for Rationing GLP-1s?
There is a shortage of GLP-1s in the U.S. But experts have differing opinions on whose responsibility it is to be rationing the drugs.
At BIO, Novo Nordisk’s Top Dealmaker Talks M&A Strategy and What’s Next After GLP-1s
Novo Nordisk’s focus on diabetes and obesity shape its business development work, but the company is also exploring other areas. Top Novo Nordisk M&A executive John McDonald discussed his company’s strategy during a session at the BIO conference in San Diego.
Using Informed Awareness to Transform Care Coordination and Improve the Clinical and Patient Experience
This eBook, in collaboration with Care Logistics, details how hospitals and health systems can facilitate more effective decision-making by operationalizing elevated awareness.
As Interest in GLP-1s Explodes, People Living With Diabetes Need Structured Support To Ensure Effective Use
By working together to build an ecosystem of support around people with diabetes, the healthcare system as a whole can ensure that no one slips through the cracks.
The Senate Attacks on Pharma Put the Industry in Jeopardy and Consumers at Risk
Singling out an industry segment won’t solve the underlying problem of healthcare costs.
Navigating Opportunities and Challenges in the GLP-1 Drug Gold Rush
GLP-1 agonists are transforming the weight loss market. Experts weighed in on the changes they’re seeing, speaking in a panel discussion during the MedCity News INVEST Conference in Chicago.
FTC Seeks More Information on the $16.5B Novo-Catalent Deal, Leading to Another Delay
Novo Holdings’ $16.5 billion planned acquisition of Catalent is facing another delay. Just weeks after Novo decided to resubmit its application to the FTC, the agency is seeking more information about the deal. This move has triggered a second 30-day delay in the antitrust review process.
Unlocking Transparency in PBM Pricing
The TSX Venture Exchange has a strong history of helping early-stage health and life sciences companies raise patient capital for research and development.
presented by
How to Help Physicians Generate More Revenue and Make Their Patients Healthier
Interest in using GLP-1 drugs to reduce obesity combined with a desire by physicians to become less dependent on insurance-based reimbursement after the recent Change Healthcare cyberattack is building.
GLP-1s Alone Are Not the Answer to America’s Obesity and Chronic Illness Crises
Obesity/overweight is a significant causal factor in chronic illness and cancer. Weight loss can help people with obesity/overweight avoid and/or manage chronic illness. GLP-1s cause weight loss. So, are GLP-1s the answer to America’s obesity and chronic illness crises? Not if we overlook a key problem at the heart of both challenges: lack of access to nutritious food in the land of plenty.
Downside of One-Size-Fits-All: Rethinking Weight-Loss Medications Strategy
A comprehensive approach to obesity management goes beyond prescribing medications for a quick fix.
Lower BMI, Raise ROI: How Physician Practices Can Boost Revenues with Turnkey Weight Management Program
The webinar, scheduled for March 6 at 2pm ET and sponsored by Build My Health, will discuss several topics related to weight management including: an overview of GLP-1 weight loss medication, automation in a subscription-based weight management program, and the rise of provider-to-consumer (PTC) models.
When Investment Rhymes with Canada
Canada has a proud history of achievement in the areas of science and technology, and the field of biomanufacturing and life sciences is no exception.
Novo Holdings Bolsters GLP-1 Production Capacity With $16.5B Catalent Buyout
After Novo Holdings acquires Catalent, it will sell three of the contract manufacturing giant’s sites to Novo Nordisk. Those facilities already make Novo Nordisk’s GLP-1 drugs for metabolic conditions, and they will help the company meet projected demand for these products in years to come.